HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term treatment with rituximab of autoimmune autonomic ganglionopathy in a patient with lymphoma.

AbstractOBJECTIVE:
To report on the response to therapy in a patient with autoimmune autonomic ganglionopathy with a high titer of an autoantibody directed against the α-3 subunit of the nicotinic acetylcholine receptor (nAChR) of the autonomic ganglia.
DESIGN:
Case report.
SETTING:
University-based referral center for autonomic dysfunction.
PATIENT:
Patient with prior indolent B-cell lymphoma who presented with symptomatic orthostatic hypotension and autonomic failure and was found to have a high titer of nAChR antibody.
INTERVENTION:
Plasma exchange and rituximab therapy (both initial 4-week therapy and maintenance therapy).
MAIN OUTCOME MEASURES:
Autonomic ganglionic antibody titer; the autonomic assessments were the presence of orthostatic hypotension, the concentration of plasma norepinephrine, and quantitative sweat testing.
RESULTS:
Treatment with rituximab followed by plasma exchange significantly decreased the nAChR antibody titers for a short time, and then the titers increased. The titers suppressed to almost undetectable levels once regular maintenance therapy with rituximab was initiated. Reduction in nAChR antibody titer resulted in a decrease in orthostatic hypotension, an increased concentration of upright plasma norepinephrine, improvement in some sweat function, and improvement in symptoms.
CONCLUSIONS:
Long-term rituximab therapy suppressed autoantibody production to undetectable levels over the course of 2 years and resulted in sustained clinical improvement in this patient with debilitating autoimmune autonomic ganglionopathy. More data are needed before rituximab therapy can be recommended as routine therapy for this disorder.
AuthorsRyan Hollenbeck, Bonnie K Black, Amanda C Peltier, Italo Biaggioni, David Robertson, Elliott F Winton, Satish R Raj
JournalArchives of neurology (Arch Neurol) Vol. 68 Issue 3 Pg. 372-5 (Mar 2011) ISSN: 1538-3687 [Electronic] United States
PMID21059985 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Autoantibodies
  • Receptors, Nicotinic
  • Rituximab
  • Norepinephrine
Topics
  • Aged
  • Antibodies, Monoclonal, Murine-Derived (therapeutic use)
  • Antineoplastic Agents (therapeutic use)
  • Autoantibodies (analysis, immunology)
  • Autoimmune Diseases of the Nervous System (complications, drug therapy, therapy)
  • Autonomic Nervous System Diseases (complications, drug therapy, therapy)
  • Blood Pressure (physiology)
  • Female
  • Ganglia, Autonomic
  • Humans
  • Hypotension, Orthostatic (etiology)
  • Lymphoma, B-Cell (complications)
  • Norepinephrine (blood)
  • Plasma Exchange
  • Receptors, Nicotinic (immunology)
  • Rituximab
  • Sweating (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: